Press Center

We invite you to a webinar on current issues in customs regulation.

Lidings’ Partner Stepan Guzey will visit Muscat, Sultanate of Oman, for a series of meetings with representatives of leading local law firms to discuss the prospects for cross-border cooperation.

From 1 September 2026, new rules for calculating remuneration for employees who are the authors of employee inventions, utility models and industrial designs will come into force. The document fundamentally changes the approach to such payments.

The Russian Ministry of Health’s draft law “On Amending Certain Legislative Acts of the Russian Federation…” (“the Draft Law”), concerning changes to the control of the circulation of medicinal products has been published on the federal portal for draft regulatory acts.

On June 1, 2026, the decision of the Bank of Russia Working Group dated June 1, 2026  No. PRG-43-11/1199 (hereinafter – “Decision”) and Presidential Decree No. 377 dated June 1, 2026 “On Amending Presidential Decree No. 95 of March 5, 2022 ‘On the Temporary Procedure for Fulfilling Obligations to Certain Foreign Creditors’” (hereinafter – “Decree No. 377”) were published, introducing changes to the current counter-sanctions regulation.

On June 9, 2026, Moscow will host the annual RAA conference on "Current Issues in Cross-Border Insolvency." The event is organized by the Russian Arbitration Association (RAA) as part of its ongoing tradition. Lidings is proud to serve as an official partner of the conference

Since the beginning of 2025, Russian courts have issued several landmark rulings in the field of personal data processing. These cases affect the interests of banks, marketplaces, solid waste management operators, employers, and online platforms. Some positions confirm long-standing approaches (withdrawal of consent does not terminate processing where a contract or legal obligation exists), while others establish new guidelines for businesses (processing of a beneficiary's data without consent, inadmissibility of contacting a previous employer without the candidate's permission).

Our review covers seven recent cases with conclusions that will help DPOs, legal teams, and information security departments minimize risks and establish compliant processes.

We invite you to a webinar on antitrust risks for pharmaceutical companies when setting prices for medicinal products.

As part of the implementation of the Strategy for the Development of the Pharmaceutical Industry through 2030, approved by Decree of the Government of the Russian Federation No. 1495-r of 7 June 2023 (“Pharma Strategy 2030”), and discussions at the “Healthy Society” forum organized by the Roscongress Foundation with the support of the Ministry of Health (16–17 March 2026, Moscow) (“Forum”), key areas of state support for domestic drug developers and manufacturers were identified, including subsidies for clinical trials .

In addition to existing support programs, subsidies for clinical trials at all stages will help overcome the financing barrier for high-risk phases of medicines clinical trials and accelerate the market launch of medicines. The combination of current and planned measures will create the legal and economic foundation for strengthening the production and technological capacity of the domestic pharmaceutical industry and increasing its presence in international markets.

Below, we will examine planned initiatives and support measures for pharmaceutical manufacturers that have already been implemented.